Novel targets in aggressive lymphoma

Area of Science:

• Hematology
• Oncology
• Immunology

Background:

• Chemoimmunotherapy with rituximab improves survival for aggressive B-cell lymphomas, but relapsed or refractory disease carries a poor prognosis.
• Novel agents have shown efficacy in relapsed disease, yet randomized trials on chemoimmunotherapy backbones have not demonstrated further survival benefits.
• Recent advancements focus on harnessing the patient's immune system for treating relapsed or refractory aggressive lymphomas.

Purpose of the Study:

• To discuss promising targets in aggressive lymphoma with the greatest potential for improving patient outcomes.
• To highlight novel therapies, their toxicities, and their potential roles in initial or subsequent treatment regimens.

Main Methods:

• Review of recent advancements in treating relapsed or refractory aggressive B-cell lymphomas.
• Discussion of novel therapeutic agents, including chimeric antigen receptor T-cells and antibody drug conjugates.
• Analysis of targeted agents and their potential use in combination therapies.

Main Results:

• Chimeric antigen receptor T-cell therapies offer potential curative options, despite challenges with toxicity and access.
• The antibody drug conjugate polatuzumab combined with chemoimmunotherapy provides survival benefits for patients unsuitable for aggressive treatments.
• Several targeted agents demonstrate efficacy but often require durable responses through combination therapies.

Conclusions:

• Emerging immunotherapies and targeted agents represent significant progress in managing relapsed or refractory aggressive lymphomas.
• These novel approaches, including CAR T-cell therapy and antibody drug conjugates, have the potential to alter the standard of care.
• Further research into combination therapies is crucial for achieving durable responses and improving long-term outcomes for patients with aggressive lymphomas.